Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Phase 2

Active, not recruiting

Conditions: Vulvar High Grade Squamous Intraepithelial Lesion
Cervical Squamous Cell Carcinoma In Situ

Interventions: Drug: Cyclophosphamide
Drug: Indomethacin
Biological: IRX-2
Other: Laboratory Biomarker Analysis
Dietary Supplement: Multivitamin
Other: Placebo
Drug: Omeprazole
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2017-08-30

Last Posted Date: 2024-10-10

Lead Sponsor: University of Southern California

Target Recruit Count: 11

Registration Number: NCT03267680

Locations: 🇺🇸
University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Procedure: Haploidentical Bone Marrow Transplantation
Drug: Hydroxyurea
Drug: Rabbit-ATG
Drug: Thiotepa
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total Body Irradiation
Drug: Mesna

First Posted Date: 2017-08-28

Last Posted Date: 2023-12-28

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 80

Registration Number: NCT03263559

Locations: 🇺🇸
Texas Children's Hospital (Baylor), Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Nicklaus Children's Hospital/University of Miami Children's Hospital, Miami, Florida, United States

and more 29 locations

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC

Phase 2

Terminated

Conditions: Graft Versus Host Disease

Interventions: Drug: Fludarabine
Drug: Clofarabine
Radiation: Full body irradiation
Drug: Cyclophosphamide
Other: stem cell transplantation
Other: nuclear cells
Drug: Thymoglobulin Injectable Product

First Posted Date: 2017-08-28

Last Posted Date: 2022-07-15

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 47

Registration Number: NCT03263767

Locations: 🇫🇷
Nantes Uh, Nantes, France

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Phase 1

Conditions: B-cell Acute Lymphocytic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: CD19 CAR-T

First Posted Date: 2017-08-28

Last Posted Date: 2017-10-20

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT03263208

Locations: 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Nivolumab With Chemotherapy in Refractory MDS

Phase 1

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Nivolumab
Drug: Fludarabine
Drug: Cytarabine
Drug: Melphalan
Drug: Azacitidine
Drug: all trans retinoic acid
Drug: Cyclophosphamide
Drug: Sildenafil

First Posted Date: 2017-08-23

Last Posted Date: 2019-04-05

Lead Sponsor: St. Petersburg State Pavlov Medical University

Target Recruit Count: 2

Registration Number: NCT03259516

Locations: 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Phase 2

Active, not recruiting

Conditions: Recurrent Primary Amyloidosis

Interventions: Drug: Dexamethasone
Drug: Cyclophosphamide
Biological: Elotuzumab
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Other: Pharmacological Study

First Posted Date: 2017-08-17

Last Posted Date: 2023-01-25

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 53

Registration Number: NCT03252600

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Levine Cancer Center, Charlotte, North Carolina, United States
🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States

and more 2 locations

Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma

Phase 1

Completed

Conditions: Synovial Sarcoma

Interventions: Biological: TBI-1301
Drug: Cyclophosphamide

First Posted Date: 2017-08-15

Last Posted Date: 2024-11-20

Lead Sponsor: Takara Bio Inc.

Target Recruit Count: 8

Registration Number: NCT03250325

Locations: 🇯🇵
National Hospital Organization Osaka National Hospital, Osaka, Japan
🇯🇵
Mie University Hospital, Tsu, Mie, Japan
🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

and more 2 locations

A Blood Stem Cell Transplant for Sickle Cell Disease

Phase 1

Active, not recruiting

Conditions: Sickle Cell Disease
Hemoglobinopathies
Thalassemia
Anemia, Sickle Cell
Sickle Cell Disorder

Interventions: Drug: Cyclophosphamide
Drug: Pentostatin
Drug: Rabbit anti-thymocyte globulin
Drug: Tacrolimus
Drug: Mycophenolate mofetil
Biological: CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant

First Posted Date: 2017-08-15

Last Posted Date: 2024-03-07

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 3

Registration Number: NCT03249831

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: Doxorubicin
Drug: Letrozole 2.5mg
Drug: Cyclophosphamide
Drug: Paclitaxel

First Posted Date: 2017-08-14

Last Posted Date: 2021-03-17

Lead Sponsor: SOLTI Breast Cancer Research Group

Target Recruit Count: 106

Registration Number: NCT03248427

Locations: 🇪🇸
Centro Oncológico MD Anderson International España, Madrid, Spain
🇪🇸
Hospital General de Catalunya, Barcelona, Spain
🇪🇸
Hospital Clinic de Barcelona, Barcelona, Spain

and more 18 locations

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Aggressive Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Myelodysplastic/Myeloproliferative Neoplasm
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Recurrent Plasma Cell Myeloma
Recurrent Small Lymphocytic Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil
Drug: Sirolimus

First Posted Date: 2017-08-11

Last Posted Date: 2024-07-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 150

Registration Number: NCT03246906

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy